Only a few days to go: We’re raising £25,000 to keep TheyWorkForYou running and make sure people across the UK can hold their elected representatives to account.

Donate to our crowdfunder

Rare Diseases

Department of Health and Social Care written question – answered on 23rd April 2018.

Alert me about debates like this

Photo of Mark Tami Mark Tami Opposition Pairing Whip (Commons)

To ask the Secretary of State for Health and Social Care, what assessment he has made of (a) the accuracy of NICE's calculation of the wider value of (i) rare disease and (ii) rarer cancer treatments and (b) the extent to which NICE accounts in that calculation for (A) additional medical benefits, (B) wider economic consequences and (C) social impact costs.

Photo of Steve Brine Steve Brine The Parliamentary Under-Secretary for Health and Social Care

The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing authoritative, evidence-based guidance for the National Health Service on whether drugs and other treatments represent an effective use of NHS resources.

NICE’s methods and processes for the assessment of drugs have been carefully developed over time and are internationally respected. NICE continues to keep its procedures under periodic review to ensure that they remain effective and fit for purpose.

In developing guidance on drugs and other treatments through its technology appraisal programme, NICE routinely takes into account all health-related costs and benefits relating to the treatment. NICE may also take into account wider costs and benefits where relevant in making its recommendations.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.